Pharmaceutical Commerce | Journals | Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

AI-driven cold chain visibility is only as reliable as the data behind it, exposing gaps between compliance, monitoring, and true product conditions.

A fixed 15.5% manufacturer rebate on patented branded drugs replaces a proposed variable, expenditure-linked mechanism after coordinated industry pressure and threats to curtail German investment and ...

Supply-chain objectives should explicitly prioritize product protection, traceability for recalls/loss, circularity, and compatibility with automated material handling systems. Key KPIs include system ...

Pairing Tennr referral intake and documentation automation with TailorMed affordability tooling is designed to surface access barriers earlier and shorten time-to-therapy for infusion and specialty ...

PBM reform scrutiny of reimbursement, rebate flow, and compensation can shift benefit conditions that determine how manufacturer-funded copay, buy-down, and support programs function at dispensing.

Tech-enabled pharmacies reflect the reality of the GLP-1 landscape: patient success depends on more than a prescription. With ...

Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains which therapeutic areas will lead DTP adoption and her five-year outlook for the model. Direct-to-patient (DTP) programs are no ...